ATE540116T1 - Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen - Google Patents
Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionenInfo
- Publication number
- ATE540116T1 ATE540116T1 AT05825667T AT05825667T ATE540116T1 AT E540116 T1 ATE540116 T1 AT E540116T1 AT 05825667 T AT05825667 T AT 05825667T AT 05825667 T AT05825667 T AT 05825667T AT E540116 T1 ATE540116 T1 AT E540116T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- start site
- aug start
- site region
- virus
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000007136 Filoviridae Infections Diseases 0.000 title 1
- 241001115402 Ebolavirus Species 0.000 abstract 3
- 241001115401 Marburgvirus Species 0.000 abstract 3
- 101150010086 VP24 gene Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 241000711950 Filoviridae Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 101150077651 VP35 gene Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000017066 negative regulation of growth Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62427704P | 2004-11-01 | 2004-11-01 | |
| US67169405P | 2005-04-14 | 2005-04-14 | |
| US11/264,444 US7524829B2 (en) | 2004-11-01 | 2005-10-31 | Antisense antiviral compounds and methods for treating a filovirus infection |
| PCT/US2005/039607 WO2006050414A2 (en) | 2004-11-01 | 2005-11-01 | Antisense antiviral compounds and methods for treating filovirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540116T1 true ATE540116T1 (de) | 2012-01-15 |
Family
ID=36319793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05825667T ATE540116T1 (de) | 2004-11-01 | 2005-11-01 | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7524829B2 (de) |
| EP (1) | EP1814596B1 (de) |
| AT (1) | ATE540116T1 (de) |
| AU (1) | AU2005302155B2 (de) |
| CA (1) | CA2584873C (de) |
| WO (1) | WO2006050414A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2351976T3 (es) * | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| DK1766012T3 (da) * | 2004-07-02 | 2011-09-19 | Avi Biopharma Inc | Antisense-antibakteriel fremgangsmåde og forbindelse |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US7834064B2 (en) * | 2005-01-03 | 2010-11-16 | Andres Mario Salazar | Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| WO2007030576A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US7838658B2 (en) * | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
| WO2007092607A2 (en) * | 2006-02-09 | 2007-08-16 | Genetech, Inc. | Treatment of hemorrhagic viral infections using a tissue factor inhibitor |
| AU2013202322B2 (en) * | 2006-05-10 | 2016-04-28 | Avi Biopharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| PL2735568T3 (pl) * | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| AP3018A (en) | 2007-03-29 | 2014-10-31 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expressionof a gene from the ebola |
| WO2008156853A2 (en) * | 2007-06-20 | 2008-12-24 | The Board Of Regents Of The University Of Texas System | Inhibition of filovirus entry into cells and uses thereof |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2008345033B2 (en) | 2007-12-28 | 2014-04-03 | Sarepta Therapeutics, Inc. | Immunomodulatory agents and methods of use |
| ES2579628T3 (es) | 2009-02-23 | 2016-08-12 | Emergent Virology Llc | Iminoazúcares y métodos de tratamiento de enfermedades virales |
| EP2400843B1 (de) * | 2009-02-24 | 2015-11-11 | United Therapeutics Corporation | Iminozucker und verfahren zur behandlung von arenaviridae-erkrankungen |
| ES2524361T3 (es) | 2009-06-12 | 2014-12-05 | United Therapeutics Corporation | Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus |
| US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
| AP3574A (en) * | 2009-08-14 | 2016-02-08 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| JP5575246B2 (ja) * | 2009-09-04 | 2014-08-20 | ユナイテッド セラピューティクス コーポレイション | ポックスウイルス感染の治療方法 |
| CA2772875A1 (en) * | 2009-09-04 | 2011-03-10 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
| EP2473046B1 (de) * | 2009-09-04 | 2014-10-22 | United Therapeutics Corporation | Iminozucker zur verwendung in der behandlung von filoviruserkrankungen |
| KR101944119B1 (ko) | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) * | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CN107693797B (zh) | 2011-05-05 | 2021-05-11 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
| KR102142689B1 (ko) | 2011-11-18 | 2020-08-10 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| EP2722047A1 (de) | 2012-10-19 | 2014-04-23 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | 2,3-Dihydroquinazolin-4(1H)-one Derivate zur Verwendung in der Behandlung von viralen Infektionen |
| US9845469B2 (en) * | 2014-02-10 | 2017-12-19 | Ohio State Innovation Foundation | Antisense oligonucleotides for treatment of spinal muscular atrophy |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| LT3554553T (lt) | 2016-12-19 | 2022-08-25 | Sarepta Therapeutics, Inc. | Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos |
| WO2019104294A1 (en) * | 2017-11-27 | 2019-05-31 | Western University Of Health Sciences | Fluorophore-labeled phosphorodiamidate morpholino oligonucleotides and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5749847A (en) | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| WO1992003454A1 (en) * | 1990-08-14 | 1992-03-05 | Isis Pharmaceuticals, Inc. | Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides |
| US6006174A (en) * | 1990-10-03 | 1999-12-21 | Interdigital Technology Coporation | Multiple impulse excitation speech encoder and decoder |
| US5495006A (en) | 1991-09-27 | 1996-02-27 | Allelix Biopharmaceuticals, Inc. | Antiviral polynucleotide conjugates |
| US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| CA2125269A1 (en) | 1991-12-23 | 1993-07-08 | Chiron Diagnostics Corporation | Hav probes for use in solution phase sandwich hybridization assays |
| US20030171311A1 (en) | 1998-04-27 | 2003-09-11 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US5738985A (en) | 1993-04-02 | 1998-04-14 | Ribogene, Inc. | Method for selective inactivation of viral replication |
| US6824976B1 (en) | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
| AU7513794A (en) * | 1993-09-10 | 1995-03-27 | E.I. Du Pont De Nemours And Company | Improved process for preparing 2-amino-4,6-dichloropyrimidine |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| DE69533515D1 (de) | 1994-10-11 | 2004-10-21 | Univ California Los Angeles | Selektive inhibierung von intern initiierter rna-translation |
| GB9510718D0 (en) | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5955318A (en) | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| WO1998012312A1 (en) | 1996-09-18 | 1998-03-26 | Vanderbilt University | Antisense gene therapy for rna viruses |
| DE69818987T2 (de) | 1997-05-21 | 2004-07-29 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford | Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) * | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
| US6258570B1 (en) | 1998-04-17 | 2001-07-10 | University Of Pittsburgh | PCR assay for bacterial and viral meningitis |
| EP1092031A2 (de) * | 1998-06-29 | 2001-04-18 | U.S. Medical Research Institute of Infectious Diseases | Marburg-virus impfstoffe |
| EP1124950B1 (de) | 1998-10-26 | 2006-07-12 | Avi Biopharma, Inc. | Auf Morpholin basierendes p53-Antisense- Oligonucleotid und dessen Verwendungen |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 ｒｎａ를 검출하는 비-침입적 방법 |
| US6875747B1 (en) | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| WO2001015511A2 (en) | 1999-09-01 | 2001-03-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| US6521438B1 (en) | 1999-11-05 | 2003-02-18 | North Carolina State University | Chemoreceptors in plant parasitic nematodes |
| US20030095953A1 (en) | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| DE29920656U1 (de) * | 1999-11-24 | 2000-02-17 | Vincent, Irvin G., Luxemburg, Wis. | Universelles Bauelement |
| CA2392685C (en) * | 1999-11-29 | 2011-02-22 | Avi Biopharma, Inc. | Antisense antibacterial method and composition |
| KR20020079768A (ko) * | 2000-01-04 | 2002-10-19 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 세포분열 조성물 및 방법 |
| KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| EP3020804A1 (de) * | 2000-07-06 | 2016-05-18 | Sarepta Therapeutics, Inc. | Umwandlung der wachstumsfaktor-beta (tgf-beta) blockierungsmittelbehandelten stammzellenzusammensetzung und verfahren |
| SG144729A1 (en) | 2000-07-06 | 2008-08-28 | Bio Merieux | Method for controlling the microbiological quality of an aqueous medium and kit therefor |
| US6673917B1 (en) | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| FR2819523B1 (fr) * | 2001-01-18 | 2003-06-13 | Jean Lemonnier | Boite sterile pour la culture de micro-organismes, ensemble et distributeur de boites |
| US6899864B2 (en) | 2001-03-30 | 2005-05-31 | Immunomedics, Inc. | Morpholino imaging and therapy |
| AU2002342057B2 (en) | 2001-10-16 | 2009-01-22 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US6828579B2 (en) * | 2001-12-12 | 2004-12-07 | Hi-Z Technology, Inc. | Thermoelectric device with Si/SiC superlattice N-legs |
| US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
| EP2330194A3 (de) | 2002-09-13 | 2011-10-12 | Replicor, Inc. | Nicht-sequenzkomplementäre antivirale Oligonukleotide |
| CA2501946C (en) | 2002-10-16 | 2014-12-23 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| JP4791043B2 (ja) | 2002-12-31 | 2011-10-12 | プロリゴ・エルエルシー | 同一固体支持体上で、２以上のオリゴヌクレオチドをタンデムに合成するための方法および組成物 |
| WO2005030800A2 (en) | 2003-08-05 | 2005-04-07 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
| EP1668145A4 (de) | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | Sense-antivirusverbindung und verfahren zur behandlung einer ssrna-virusinfektion |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2007030576A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| WO2007030691A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
-
2005
- 2005-10-31 US US11/264,444 patent/US7524829B2/en not_active Expired - Lifetime
- 2005-11-01 AU AU2005302155A patent/AU2005302155B2/en not_active Ceased
- 2005-11-01 EP EP05825667A patent/EP1814596B1/de not_active Expired - Lifetime
- 2005-11-01 AT AT05825667T patent/ATE540116T1/de active
- 2005-11-01 WO PCT/US2005/039607 patent/WO2006050414A2/en not_active Ceased
- 2005-11-01 CA CA2584873A patent/CA2584873C/en not_active Expired - Fee Related
-
2006
- 2006-05-11 US US11/433,840 patent/US7507196B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 US US12/402,464 patent/US8168604B2/en active Active
- 2009-03-11 US US12/402,461 patent/US8030292B2/en active Active
- 2009-03-11 US US12/402,455 patent/US8030291B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1814596B1 (de) | 2012-01-04 |
| AU2005302155A1 (en) | 2006-05-11 |
| US20090186847A1 (en) | 2009-07-23 |
| US8030292B2 (en) | 2011-10-04 |
| CA2584873C (en) | 2017-04-18 |
| US7507196B2 (en) | 2009-03-24 |
| US8168604B2 (en) | 2012-05-01 |
| US7524829B2 (en) | 2009-04-28 |
| US8030291B2 (en) | 2011-10-04 |
| US20090186848A1 (en) | 2009-07-23 |
| US20060205693A1 (en) | 2006-09-14 |
| EP1814596A4 (de) | 2010-06-16 |
| AU2005302155B2 (en) | 2012-09-06 |
| US20060281701A1 (en) | 2006-12-14 |
| CA2584873A1 (en) | 2006-05-11 |
| WO2006050414A2 (en) | 2006-05-11 |
| WO2006050414A3 (en) | 2007-11-01 |
| US20090186849A1 (en) | 2009-07-23 |
| EP1814596A2 (de) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE540116T1 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| WO2006047683A3 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| DE602007006457D1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| PH12021551007A1 (en) | S-antigen transport inhibiting oligonucleotide polymers and methods | |
| EP1937278A4 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von picornavirus-infektion | |
| DK1692265T3 (da) | Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner | |
| EP1802777A4 (de) | Antivirale antisense-verbindung und verfahren zur behandlung einer ssrna-virusinfektion | |
| WO2007030691A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| EP1623012A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| ATE552347T1 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| ATE491791T1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| WO2005013905A3 (en) | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| ATE505541T1 (de) | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai | |
| PH12022553394A1 (en) | Conjugate of double-stranded sirna analogue | |
| RU2008121265A (ru) | Малые интерферирующие олигонуклеотиды, содержащие арабинозо-модифицированные нуклеотиды | |
| RU2008117439A (ru) | Аптамеры, содержащие модифицированные арабинозой нуклеотиды | |
| AU2013205445B2 (en) | Antisense antiviral compound and method for treating picornavirus infection |